fluticasone propionate


Also found in: Medical, Acronyms, Wikipedia.

flu·tic·a·sone propionate

 (flo͞o-tĭk′ə-sōn′, -zōn′)
n.
A synthetic corticosteroid, C25H31F3O5S, used as a topical anti-inflammatory and antipruritic, as a nasal spray in the treatment of rhinitis, and as an inhalant, in combination with salmeterol, in the treatment of asthma and chronic obstructive pulmonary disease.

[flu(oro)- + tic- (probably shortening and rearrangement of carbothioate, one of its constituents) + (meth)asone (as in dexamethasone).]
References in periodicals archive ?
Analysis of the 12-week efficacy data revealed no statistically significant differences among the fluticasone propionate groups.
A dose-ranging study of fluticasone propionate aqueous nasal spray for seasonal allergic rhinitis assessed by symptoms, rhinomanometry, and nasal cytology.
The company said fluticasone propionate 100, 250, 500 mcg and salmeterol 50 mcg inhalation powder is the generic version of GlaxoSmithKline's Advair Diskus, which is indicated for treating asthma and the maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).
According to the company, the fluticasone propionate 100, 250, 500 mcg and salmeterol 50 mcg inhalation powder is the generic version of GlaxoSmithKline's Advair Diskus, which is indicated for the treatment of asthma and the maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).
Patients with clinically stable asthma were then randomized to continue fluticasone/salmeterol or to step down to fluticasone propionate alone (100 [micro]g b.
The researchers used a database representing 20 health plans with more than 5 million patients to identify 4,184 patients who started fluticasone propionate monotherapy for asthma and 3,846 who started montelukast monotherapy between January 1999 and June 2000.
21059 Fluticasone Propionate 100 Mcg X 1 Dose X 120 Mdi Inno Nasal Spray
The primary outcome was a reduction in inhaled fluticasone propionate dose.
8,765,725) covering AC-155 Fluticasone Propionate Nano-crystalline Compositions from the US Patent and Trademark Office, it was reported yesterday.
In a study sponsored by GlaxoSmithKline, 472 children aged 12-47 months with persistent mild to moderate asthma received 100 [micro]g fluticasone propionate (FP) twice daily; another 154 children were treated with 5 mg sodium cromoglycate (SCG) four times daily.